OMEPRAZOLE Drug Patent Profile

Which patents cover Omeprazole, and what generic alternatives are available?

Omeprazole is a drug marketed by Actavis Labs Fl Inc, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Impax Labs, Lannett Co Inc, Lupin Ltd, Pharmobedient, Sandoz, Strides Pharma, Teva Pharms Usa, Xiromed, Zydus Pharms Usa Inc, Dexcel Pharma, Dr Reddys, Sun Pharm, Dexcel, Ajanta Pharma Ltd, Anda Repository, Aurolife Pharma Llc, Chartwell Rx, Perrigo R And D, Sciegen Pharms, Strides Pharma Intl, Zydus, Zydus Pharms, Novitium Pharma, Aurobindo Pharma Ltd, Spil, Marksans Pharma, and P And L. and is included in forty-eight NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has four patent family members in three countries.

The generic ingredient in OMEPRAZOLE is omeprazole magnesium. There are one hundred and thirty-one drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Omeprazole

A generic version of OMEPRAZOLE was approved as omeprazole magnesium by DR REDDYS LABS LTD on June 5^th, 2009.

Summary for OMEPRAZOLE

International Patents:	4
US Patents:	2
Applicants:	34
NDAs:	48
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OMEPRAZOLE

Paragraph IV (Patent) Challenges for OMEPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OMEPRAZOLE	Delayed-release Tablets	omeprazole	20 mg	022032	1	2015-06-03

US Patents and Regulatory Information for OMEPRAZOLE

OMEPRAZOLE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	203290-002	May 25, 2018	AB	RX	No	No
Teva Pharms Usa	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	204661-002	Jun 13, 2017		DISCN	No	No
Pharmobedient	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	205070-002	Jun 29, 2018		DISCN	No	No
Marksans Pharma	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	218829-001	Aug 7, 2025		OTC	No	No
Dexcel Pharma	OMEPRAZOLE	omeprazole	TABLET, DELAYED RELEASE;ORAL	022032-001	Dec 4, 2007		OTC	Yes	Yes
Aurolife Pharma Llc	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	204922-002	Aug 19, 2016	AB	RX	No	No

International Patents for OMEPRAZOLE

See the table below for patents covering OMEPRAZOLE around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	130602
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
Australia	2017285390
European Patent Office	1187599	FORMULATION DE BENZIMIDAZOLE STABLE (STABLE BENZIMIDAZOLE FORMULATION)
World Intellectual Property Organization (WIPO)	0078284

Supplementary Protection Certificates for OMEPRAZOLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105

Omeprazole (Proton Pump Inhibitor): Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

Omeprazole is a long-established, widely genericized proton pump inhibitor (PPI) with mature, price-competitive markets in most geographies. The investment case is less about pipeline optionality and more about portfolio positioning, execution in generics and branded renewals where permitted, and supply-chain resilience in a mature commodity-like segment.

Where does omeprazole sit in the market cycle?

Omeprazole is a “mature, high-volume, low-differentiation” drug class in most markets because the active ingredient has been off patent for years and is extensively genericized. Revenue growth is driven primarily by:

• Market access and payer coverage
• Conversion between pack sizes and dosing regimens
• Launch speed for high-quality generics (bioequivalence and formulation competitiveness)
• Geographic expansion and wholesaler contracting
• IP-safe line extensions (limited; mostly brand-layer strategy where brands persist)

Practical investor takeaway: The fundamentals behave like a broad generics category rather than a typical patented growth story. Competitive advantage is operational (cost, supply, regulatory throughput) and commercial (tender wins, contracting discipline).

What is the competitive landscape and intensity of pricing pressure?

Omeprazole is sold globally as immediate-release and delayed-release formulations and is one of the most widely dispensed PPIs. Competitive intensity is high because multiple manufacturers can supply after bioequivalence approval.

Key competitive implications for investors

• Price erosion is structurally likely: large number of generic SKUs and manufacturers supports downtrend pressure over time.
• Tender and formulary dynamics dominate: winning a reimbursement category often yields more value than incremental promotional spend.
• Quality and manufacturing compliance become decisive: recall risk, supply disruptions, and batch failures carry disproportionate commercial cost in mature markets.

Investment lens: Evaluate assets as supply-and-regulatory businesses: manufacturing capacity, compliance record, and ability to defend contracting terms.

What are the demand fundamentals for omeprazole?

Demand for omeprazole is anchored in chronic and recurring indications where PPIs are standard care:

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease (including maintenance in relevant populations)
• Dyspepsia-related reflux conditions (where applicable by local guidelines)
• Stress ulcer prophylaxis in institutional settings (depending on formulation approvals)
• Part of combination regimens for Helicobacter pylori eradication (in relevant labeled combinations)

Demand stability drivers

• Condition prevalence and physician prescribing inertia
• Ongoing chronic usage for GERD in many patient populations
• Continued payer coverage in many countries because of established efficacy and safety profiles

Demand risk drivers

• Guideline shifts (where PPIs are limited in scope or duration)
• Substitution to other PPIs (patients switch within class based on access and tolerance)
• Local price cuts tied to generic price regulation

How does clinical evidence translate into commercial resilience?

Omeprazole’s clinical position is backed by long real-world use and evidence-based pharmacology as a PPI that reduces gastric acid secretion. This supports durable payer acceptance and pharmacist-level substitution patterns where allowed.

Class-level properties that matter commercially

• High physician familiarity reduces switching friction across generics when substitutable
• Consistent efficacy expectations support stable prescribing volume
• Safety perceptions remain favorable due to decades of use, which supports continued formulary inclusion

Caution for investors: “Stable clinical acceptance” does not eliminate economic pressure; it mainly helps preserve demand as the brand lifecycle transitions to commoditized generic volume.

What are the regulatory and IP realities affecting investment returns?

Omeprazole is not a value-driver via primary patent exclusivity in most markets today. The economic floor is set by:

• Bioequivalence and formulation compliance for generics
• Manufacturing quality systems and inspection performance
• Regulatory speed to market and lifecycle management of the SKU catalog

Regulatory requirements and standards for PPI generics are supported by established frameworks for generic drug approval in major markets:

• US: abbreviated approval path under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman framework) with bioequivalence expectations for generics (source: FDA) [1]
• EU: centralized and national generic approval routes with bioequivalence requirements (source: EMA) [2]

Investment consequence: Returns are more sensitive to execution and cost curve position than to differentiation.

What product portfolio levers still work in a commodity market?

Even in mature markets, portfolio construction can affect revenue and margin durability:

1. Formulation strategy

   • Maintain a robust mix of strengths and dosage forms aligned with prescribing habits and tender specs.
   • Ensure consistent supply for high-velocity pack sizes.

2. Line extensions where permitted

   • New presentations, coatings, or dosing strengths can win shelf and tender placement if they meet local needs.

3. Concentration on supply reliability

   • Manufacturing redundancy, batch release stability, and strong QA reduce lost sales from shortages or recalls.

4. Institutional contracting

   • Hospitals and public tender systems can stabilize demand when supply is dependable and pricing is competitive.

What are the key financial drivers to model for omeprazole?

For investors, the dominant financial levers are:

Margin drivers

• Ex-factory cost and yields: API sourcing terms, manufacturing efficiency, and yield rates.
• Regulatory and quality cost: batch release testing, stability programs, and compliance.
• Pricing outcomes from tenders: lowest price often determines award; value depends on logistics and contract terms.
• Mix: pack sizes, strength distribution, branded vs generic share where applicable.

Volume drivers

• Formulary penetration and replacement cycles
• Conversion from competitor SKUs based on tender awards and availability
• Geographic expansion into markets with slower erosion or different competitive intensity

Risk drivers

• Supply shocks: plant downtime or quality holds
• Regulatory enforcement: warning letters, import alerts, or product-specific restrictions
• Counterparty risk: API and raw material procurement continuity

How should an investor structure an “asset view” of omeprazole exposure?

The highest-fit investment exposures usually fall into one of three buckets:

1. Generic market manufacturing and distribution platform

   • Invest where supply and compliance capabilities support winning volume at scale.

2. Portfolio investor with liquid generic revenues

   • Treat omeprazole as cash-generation exposure; value comes from stable throughput and cost leadership.

3. Brand-adjacent or tender-led commercial operators

   • Where local markets preserve brand-like revenue via contracts, explore lifecycle options around packaging and tender compliance.

Cross-bucket decision point: Investors should weight “execution probability” more than “innovation probability,” since most upside is tied to operational throughput and contracting outcomes rather than clinical novelty.

Which data anchors support fundamental plausibility for omeprazole demand?

Regulatory and labeling frameworks support continued use in acid-related disorders. Evidence-based prescribing persists because PPIs are a standard of care for acid suppression.

Regulatory context:

• FDA’s generic approval standards and abbreviated approval pathway are applicable to generics and bioequivalent products [1]
• EMA provides overarching EU regulatory structures for medicines and generics in support of bioequivalence-based approval processes [2]

What are the main geographies and channel dynamics to consider?

Even without granular revenue breakdown for each platform, investors typically face three channel realities:

• Retail pharmacy substitution: strong substitution lowers brand differentiation.
• Public tender and payer contracting: price and availability drive share.
• Hospital/institutional procurement: supply reliability and compliance reduce operational losses.

Investor action: Map exposure by channel mix because pricing elasticity differs across retail vs tender vs institutional channels.

What is the investment scenario under base, upside, and downside cases?

Use a scenario approach that treats omeprazole as a commoditized product with execution-driven variance.

Base case

• Continued generic volume growth in some markets offset by ongoing price erosion.
• Modest margin compression as competitors increase supply.
• Investment returns depend on maintaining manufacturing cost advantage and tender competitiveness.

Upside case

• Tender awards shift toward your SKUs due to supply reliability and compliance.
• Mix improves via higher-value pack sizes or dosage strengths aligned with formulary preferences.
• Procurement terms on API and excipients improve and stabilize costs.

Downside case

• Competitive entry leads to rapid price resets in core markets.
• Supply interruptions, batch failures, or regulatory actions reduce availability.
• Contract renewals occur at lower net pricing, compressing margins faster than expected.

Key Takeaways

• Omeprazole is a mature, heavily genericized PPI where pricing pressure is structural and returns depend primarily on execution: manufacturing cost, regulatory throughput, and tender contracting.
• Demand is stable due to chronic acid-related indications and established clinical positioning, but revenue growth is typically limited and volatility arises from pricing and supply rather than from clinical adoption.
• The best investment setups treat omeprazole exposure as a cash-generation or platform asset: defend market share through supply reliability and quality performance, and build margin resilience via procurement and mix optimization.
• Scenario modeling should prioritize price erosion paths and supply interruption risk, because those variables usually dominate mature generics outcomes.

FAQs

1. Is omeprazole still a high-growth drug?
   No. In most markets it is mature and genericized; growth comes mainly from volume and channel/tender wins rather than from innovation-led adoption.

2. What drives profit for omeprazole in generic markets?
   Manufacturing unit economics, regulatory and quality execution, and net pricing outcomes from tenders and payer contracting.

3. What are the biggest risks for an omeprazole-focused investment?
   Rapid competitive price resets and supply interruptions from manufacturing or compliance issues.

4. Does clinical acceptance protect omeprazole demand?
   Yes at the class level; PPIs remain standard therapy for acid-related disorders, supporting demand stability even as brands shift to generics.

5. What should an investor prioritize operationally?
   Cost curve leadership, batch release reliability, inspection readiness, and tender/commercial contracting discipline.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Generic Drug User Fees and FDA’s Abbreviated New Drug Application (ANDA) pathway. FDA. https://www.fda.gov/
[2] European Medicines Agency. (n.d.). Medicines: Generics and biosimilars (regulatory framework and approval concepts). EMA. https://www.ema.europa.eu/